These results were similar to previous reports showing that EGFR mutations account for 30%–40% of non‐small cell lung cancer (NSCLC) and 40%–55% of lung adenocarcinoma and that del19 mutations account for 40%–49% and 46%–59%, respectively, whereas L858R mutations account for 39%–47% and 25%–38% of EGFR mutations among Asians and Caucasians, respectively.21, 22, 23, 24. Here, EGFR is linked to non-small cell lung carcinoma.